Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANC002
MIFTS: 45

Anca-Associated Vasculitis

Categories: Rare diseases, Immune diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Anca-Associated Vasculitis

About this section

MalaCards integrated aliases for Anca-Associated Vasculitis:

Name: Anca-Associated Vasculitis 53
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 53 73
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 53
Aav 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 73 C2717865
Sources

Summaries for Anca-Associated Vasculitis

About this section
NIH Rare Diseases : 53 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria, result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear. Treatment includes cyclophosphamide,  glucocorticoids and other autoimmune drugs such as rituximab. 

MalaCards based summary : Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to rapidly progressive glomerulonephritis and vasculitis. An important gene associated with Anca-Associated Vasculitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs alemtuzumab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, lung and kidney.

Sources

Related Diseases for Anca-Associated Vasculitis

About this section

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 rapidly progressive glomerulonephritis 30.8 MPO PRTN3
2 vasculitis 30.5 MPO PRTN3 SERPINA1 TNF
3 cytomegalovirus infection 29.5 IL6 TNF
4 pneumonia 29.4 IL6 MPO TNF
5 microscopic polyangiitis 29.1 HLA-DRB1 MPO TNF
6 ulcerative colitis 29.0 IL6 MPO TNF
7 colitis 29.0 IL6 MPO TNF
8 arthritis 29.0 HLA-DRB1 IL6 TNF
9 common variable immunodeficiency 28.9 CTLA4 IL6 TNF
10 mixed connective tissue disease 28.8 HLA-DRB1 IL6 TNF
11 connective tissue disease 28.7 HLA-DRB1 IL6 TNF
12 lung disease 28.6 MPO PRTN3 SERPINA1 TNF
13 rheumatoid arthritis 27.3 CTLA4 HLA-DRB1 HMGB1 IL6 PRTN3 TNF
14 wegener granulomatosis 27.2 CTLA4 IL6 MPO PRTN3 SERPINA1 TNF
15 systemic lupus erythematosus 26.7 CTLA4 HLA-DRB1 HMGB1 IL6 MPO PRTN3
16 monoclonal paraproteinemia 10.8 MPO PRTN3
17 pulmonary hemosiderosis 10.7 MPO PRTN3
18 chronic maxillary sinusitis 10.7 MPO PRTN3
19 arteritic anterior ischemic optic neuropathy 10.7 MPO PRTN3
20 chronic orbital inflammation 10.6 CTLA4 PRTN3
21 multiple cranial nerve palsy 10.6 MPO PRTN3
22 hydrarthrosis 10.5 IL6 PRTN3
23 hypersensitivity reaction type iii disease 10.5 IL6 MPO
24 type 1 diabetes mellitus 12 10.5 CTLA4 HLA-DRB1
25 autoimmune addison disease 10.5 CTLA4 HLA-DRB1
26 anterior uveitis 10.4 CTLA4 IL6
27 hand, foot and mouth disease 10.4 HMGB1 IL6
28 pemphigus foliaceus 10.4 CTLA4 HLA-DRB1
29 transient arthritis 10.4 IL6 SERPINA1
30 fibromyalgia 10.3 IL6 SERPINA1
31 rheumatoid arthritis, systemic juvenile 10.3 HLA-DRB1 IL6
32 posterior scleritis 10.2 PRTN3 TNF
33 viral meningitis 10.2 IL6 SERPINA1
34 polyarteritis nodosa 10.2 IL6 MPO PRTN3
35 autoimmune inner ear disease 10.2 MPO TNF
36 glomerulonephritis 10.2
37 asbestosis 10.2 IL6 SERPINA1
38 staphylococcal toxic shock syndrome 10.2 HMGB1 TNF
39 otitis media 10.1
40 macrophage activation syndrome 10.1 HMGB1 TNF
41 cerebritis 10.1
42 lupus erythematosus 10.1
43 middle ear disease 10.1 PRTN3 TNF
44 graves' disease 10.0 CTLA4 HLA-DRB1 MPO
45 crescentic glomerulonephritis 10.0
46 endotheliitis 10.0
47 diffuse alveolar hemorrhage 10.0
48 pleural disease 10.0 MPO TNF
49 proctitis 10.0 MPO TNF
50 mycobacterium abscessus 10.0 SERPINA1 TNF

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis
Sources

Symptoms & Phenotypes for Anca-Associated Vasculitis

About this section
Sources

Drugs & Therapeutics for Anca-Associated Vasculitis

About this section

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
6
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 446-86-6 2265
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
11
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
13 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
14 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
16 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
17 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3,Not Applicable
18 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
19 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
20 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
22 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
24 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
26 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Vitamin B Complex Phase 4,Phase 3,Phase 2
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
31 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
32 Antibodies, Antineutrophil Cytoplasmic Phase 4,Phase 3,Phase 2,Not Applicable
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3,Not Applicable
35 Prednisolone phosphate Phase 4,Phase 2,Phase 3,Not Applicable
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
38 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
40 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
43 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
44 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
45 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Not Applicable
46 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
47 Tin Fluorides Phase 4,Phase 3
48 Folate Nutraceutical Phase 4,Phase 3,Phase 2
49 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2
50
Abatacept Approved Phase 3,Phase 1,Phase 2 332348-12-6 10237

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Unknown status NCT00128895 Phase 4 azathioprine
2 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
3 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
4 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
5 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
6 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
7 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
8 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Recruiting NCT02749292 Phase 4 Rituximab
9 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
10 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Suspended NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
11 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
12 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
13 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
14 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
15 Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery Unknown status NCT01297959 Phase 3 E-101 Solution 300 GU/ml;Saline solution
16 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
17 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
18 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
19 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
20 Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
21 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Completed NCT00987389 Phase 3 Glucocorticoids
22 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
23 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
24 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
25 Etanercept for Wegener's Granulomatosis Completed NCT00005007 Phase 2, Phase 3 Etanercept
26 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
27 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Recruiting NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
28 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
29 Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Recruiting NCT02108860 Phase 3 Abatacept;placebo
30 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
31 The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
32 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
33 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
34 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
35 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
36 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
37 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
38 Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis Terminated NCT01446211 Phase 3 Gusperimus + glucocorticoids;cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
39 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
40 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
41 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
42 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Completed NCT01363388 Phase 2 Placebo;CCX168
43 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Completed NCT00293072 Phase 2 Rituximab
44 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
45 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
46 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
47 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis Completed NCT00530075 Phase 2 Gusperimus
48 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis Completed NCT00468208 Phase 1, Phase 2 Abatacept
49 Daclizumab to Treat Wegener's Granulomatosis Completed NCT00040248 Phase 2 Daclizumab
50 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab

Search NIH Clinical Center for Anca-Associated Vasculitis

Sources

Genetic Tests for Anca-Associated Vasculitis

About this section
Sources

Anatomical Context for Anca-Associated Vasculitis

About this section

MalaCards organs/tissues related to Anca-Associated Vasculitis:

41
Neutrophil, Lung, Kidney, Skin, T Cells, B Cells, Bone
Sources

Publications for Anca-Associated Vasculitis

About this section

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 318)
# Title Authors Year
1
An Autopsy Case of Myeloperoxidase-anti-neutrophil Cytoplasmic Antibody (MPO-ANCA) -associated Vasculitis Accompanied by Cryoglobulinemic Vasculitis Affecting the Kidneys, Skin, and Gastrointestinal Tract. ( 29709950 )
2018
2
The adenosinergic system: a potential player in the pathogenesis of ANCA-associated vasculitis? ( 29745882 )
2018
3
Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis. ( 29663157 )
2018
4
Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. ( 29929470 )
2018
5
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. ( 29885746 )
2018
6
Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. ( 29606398 )
2018
7
Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. ( 29887327 )
2018
8
Sweet's Syndrome Mimicking ANCA-Associated Vasculitis. ( 29355513 )
2018
9
PR3-ANCA: a potential biomarker of disease activity for propylthiouracil-induced ANCA-associated vasculitis. ( 29888703 )
2018
10
Cocaine and ANCA associated vasculitis-like syndromes - A case series. ( 29108823 )
2018
11
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. ( 29371340 )
2018
12
Avacopan in the treatment of ANCA-associated vasculitis. ( 29718732 )
2018
13
Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. ( 29808456 )
2018
14
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. ( 29695498 )
2018
15
Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis. ( 29611402 )
2018
16
ANCA associated vasculitis in patients from Saudi Arabia. ( 29643885 )
2018
17
ANCA-associated Vasculitis in a Case of Congenital Leptin Deficiency. ( 29937567 )
2018
18
Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. ( 29379322 )
2018
19
Correction to: Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. ( 29971582 )
2018
20
Correction: Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. ( 29358455 )
2018
21
Methimazole-induced ANCA-associated vasculitis with diffuse alveolar haemorrhage. ( 29760925 )
2018
22
Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report. ( 29954345 )
2018
23
Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy? ( 29921573 )
2018
24
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). ( 29695500 )
2018
25
Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. ( 29902982 )
2018
26
Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study. ( 29790004 )
2018
27
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. ( 28733791 )
2017
28
Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis. ( 29247314 )
2017
29
Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. ( 29119480 )
2017
30
Intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator (rt-PA) therapy for acute cerebral infarction in a patient with ANCA-associated vasculitis. ( 28740062 )
2017
31
Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. ( 28062909 )
2017
32
Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis. ( 29185962 )
2017
33
Pupillary autonomic dysfunction in patients with ANCA-associated vasculitis. ( 28864843 )
2017
34
Comparison of Localized and Systemic Otitis Media With ANCA-associated Vasculitis. ( 28885482 )
2017
35
HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vasculitis through enhancing endothelium-neutrophil interactions. ( 28181422 )
2017
36
Duration of maintenance therapy for ANCA-associated vasculitis: more questions than answers. ( 28735280 )
2017
37
Response to: 'Mortality in ANCA-associated vasculitis: mission incomplete' by Moiseev et al. ( 28710096 )
2017
38
Spectrum of ANCA-Associated Vasculitis. ( 28868585 )
2017
39
Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis. ( 29287588 )
2017
40
Serum creatinine level and ESR values associated to clinical pathology types and prognosis of patients with renal injury caused by ANCA-associated vasculitis. ( 29285157 )
2017
41
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis. ( 29201630 )
2017
42
Towards precision medicine in ANCA-associated vasculitis. ( 29045715 )
2017
43
Do you know otitis media with ANCA-Associated Vasculitis (OMAAV)? ( 29264079 )
2017
44
MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination. ( 29255476 )
2017
45
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. ( 29247107 )
2017
46
Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over. ( 28916770 )
2017
47
A Case of Crescentic Glomerulonephritis Complicated with Hypocomplementemic Urticarial Vasculitis Syndrome and ANCA-Associated Vasculitis. ( 29594143 )
2017
48
Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. ( 29336783 )
2017
49
Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ( 28940198 )
2017
50
Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective. ( 27671907 )
2017
Sources

Variations for Anca-Associated Vasculitis

About this section
Sources

Expression for Anca-Associated Vasculitis

About this section
Search GEO for disease gene expression data for Anca-Associated Vasculitis.
Sources

Pathways for Anca-Associated Vasculitis

About this section

Pathways related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.52 CTLA4 HLA-DRB1 HMGB1 IL6 MPO PRTN3
2
Allograft rejection 1 37
Show member pathways
 12.55 CTLA4 HLA-DRB1 IL6 TNF
3
Th17 cell differentiation 37
Show member pathways
 12.2 HLA-DRB1 IL6 TNF
4
T cell receptor signaling pathway 37
Show member pathways
 12.18 CTLA4 IL6 TNF
5
HTLV-I infection 37
12.17 HLA-DRB1 IL6 TNF
6
Folate Metabolism 1
Show member pathways
 12.04 IL6 MPO TNF
7
Tuberculosis 37
11.92 HLA-DRB1 IL6 TNF
8
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.64 IL6 MPO TNF
9
Hematopoietic cell lineage 37
11.53 HLA-DRB1 IL6 TNF
10
Lung fibrosis 1
11.23 IL6 SERPINA1 TNF
11
Rheumatoid arthritis 37
11.21 CTLA4 HLA-DRB1 IL6 TNF
12
African trypanosomiasis 37
11.12 IL6 TNF
13
IL-10 Pathway 64
11.11 IL6 TNF
14
Development and heterogeneity of the ILC family 1
11.06 IL6 TNF
15
Antifolate resistance 37
11.04 IL6 TNF
16
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 61
10.99 HMGB1 MPO
17
Transcription factor regulation in adipogenesis 1
10.82 IL6 TNF
18
Cytokines and Inflammatory Response 1
10.81 HLA-DRB1 IL6 TNF
19
Overview of nanoparticle effects 1
10.74 IL6 TNF
20
LDL Oxidation in Atherogenesis 64
10.64 MPO TNF
21
amb2 Integrin signaling 1
10.61 HMGB1 IL6 MPO TNF
Sources

GO Terms for Anca-Associated Vasculitis

About this section

Cellular components related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 GHRL HMGB1 IL6 MPO PRTN3 SERPINA1
2 extracellular space GO:0005615 9.17 GHRL HMGB1 IL6 MPO PRTN3 SERPINA1

Biological processes related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.76 CTLA4 HLA-DRB1 IL6 TNF
2 neutrophil degranulation GO:0043312 9.73 HMGB1 MPO PRTN3 SERPINA1
3 regulation of signaling receptor activity GO:0010469 9.67 GHRL HMGB1 IL6 TNF
4 negative regulation of T cell proliferation GO:0042130 9.57 CTLA4 HLA-DRB1
5 negative regulation of endothelial cell proliferation GO:0001937 9.56 GHRL TNF
6 positive regulation of apoptotic process GO:0043065 9.56 CTLA4 HMGB1 IL6 TNF
7 acute-phase response GO:0006953 9.55 IL6 SERPINA1
8 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.54 GHRL HLA-DRB1
9 negative regulation of interferon-gamma production GO:0032689 9.52 HLA-DRB1 HMGB1
10 positive regulation of sprouting angiogenesis GO:1903672 9.51 GHRL HMGB1
11 positive regulation of vascular endothelial cell proliferation GO:1905564 9.49 GHRL HMGB1
12 positive regulation of chemokine production GO:0032722 9.48 IL6 TNF
13 negative regulation of growth of symbiont in host GO:0044130 9.4 MPO TNF
14 inflammatory response to antigenic stimulus GO:0002437 9.32 HLA-DRB1 HMGB1
15 negative regulation of lipid storage GO:0010888 9.16 IL6 TNF
16 response to glucocorticoid GO:0051384 9.13 HMGB1 IL6 TNF
17 positive regulation of interleukin-6 production GO:0032755 8.8 HMGB1 IL6 TNF

Molecular functions related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 HMGB1 IL6 TNF
Sources

Sources for Anca-Associated Vasculitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....